Resistell News:

Nature Communications publishes Resistell's groundbreaking AST platform

Nature Communications publishes Resistell's groundbreaking AST platform
Resistell News:

Nature Communications publishes Resistell's groundbreaking AST platform

Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).

More
Nature Communications publishes Resistell's groundbreaking AST platform

Latest news

Antimicrobial resistance is one of the top-10 global public health threats facing humanity
13th June 2022

Antimicrobial resistance is one of the top-10 global public health threats facing humanity

To celebrate its 15th anniversary Venture Kick issued movie series about the impact VK alumni have on solving the most pressing global issues. See Resistell in an episode about antibiotic resistance. Thank you for featuring us!
More
Resistell initiates a research project funded by an independent grant from Pfizer AG
20th April 2022

Resistell initiates a research project funded by an independent grant from Pfizer AG

Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell’s antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.
More
Resistell announces completion of clinical pilot performance evaluation study
15th December 2021

Resistell announces completion of clinical pilot performance evaluation study

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.
More
SPEARHEAD launches to address the silent pandemic of antimicrobial resistance (AMR)
13th December 2021

SPEARHEAD launches to address the silent pandemic of antimicrobial resistance (AMR)

Resistell is proud to be a part of SPEARHEAD project which launches to address the silent pandemic of antimicrobial resistance (AMR).
More
Resistell is proud to be featured in the
30th November 2021

Resistell is proud to be featured in the "Startup Guide Basel Area".

Resistell is proud to be featured in the "Startup Guide Basel Area".
More